Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04922307 · ClinicalTrials.gov registry record · NA
Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer
A NA study of Kidney Cancer, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 3
- Study locations
NCT04922307: Active NA study of Kidney Cancer, sponsored by Vanderbilt University Medical Center.
NCT04922307 is a NA study of Kidney Cancer that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 240 participants, below the 876-participant average among 60 other Kidney Cancer trials with a reported enrollment target (73% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04922307, a NA study of Kidney Cancer, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 3
- Study locations
Study Summary
The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.
Primary Outcome
The primary goal of the study is to evaluate the impact of the blood sparing techniques on the reduction of allogenic blood transfusion in locally advanced kidney cancer. The total number of allogenic blood units used at the end of each case will be assessed
Conditions Studied
Interventions
- PROCEDURE Blood Sparing Protocol
- PROCEDURE Standard Blood Replacement
Study Locations (3)
Florida
- H. Lee Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Institute at Emory University - Atlanta
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2021-07-23 |
| Est. Completion | 2027-06-15 |
| Phase | NA |
What the registry record for NCT04922307 still lists
NCT04922307 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 876-participant average among 60 other Kidney Cancer trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 2 interventions - of which Blood Sparing Protocol is the first listed.
NCT04922307 reports a single indexed study location in Florida, Georgia, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04922307 about?
NCT04922307 is a clinical study titled "Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer". The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, as...
What is the current status of trial NCT04922307?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2021-07-23. Estimated completion is 2027-06-15.
What conditions does trial NCT04922307 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT04922307?
The interventions under investigation include: Blood Sparing Protocol (PROCEDURE), Standard Blood Replacement (PROCEDURE).
Who is sponsoring clinical trial NCT04922307?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04922307 being conducted?
This trial has 3 study locations across Florida, Georgia, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04922307's enrollment target sits among peer trials
240 13th of 60 higher than 47 of 60 other Kidney Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
RECRUITING · NA
-
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
RECRUITING · NA
-
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
RECRUITING · NA
-
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
RECRUITING · NA
-
Designing Visual Tools to Enhance Cancer Surgeon Decision-making
RECRUITING · NA
-
Integrated Actionable Aging Assessment for Cancer Patients Pilot
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI